How do I buy Tenax Therapeutics, Inc. Common Stock (TENX) stock?

Buying Tenax Therapeutics, Inc. Common Stock (TENX) stock is now easy and instant through the Gotrade app. Download the Gotrade app from the App Store or Google Play. Create an account and verify your identity. Make a deposit. Search for the code "TENX", then tap "Trade". Tap the "Buy" button. Enter the amount you want to buy. You have two options: Buy TENX by number of shares. Buy fractional shares in dollars, starting from $1. Swipe up to confirm your order, and you're done!

How do I tell if TENX is expensive or cheap?

There's no single perfect answer, but common approaches include: Compare valuation (e.g., P/E, P/S) against historical averages or competitors. Review revenue and earnings growth. Check margins and cash flow. Evaluate business outlook and the company's position within its industry. You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Tenax Therapeutics, Inc. Common Stock (TENX) Stock

Q: What is the minimum investment for TENX on Gotrade?

On Gotrade , you don't have to buy a full share. With fractional shares, you can start investing in Tenax Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

NASDAQ · TENX

Trade TENX

Key stats

Market cap: $76.96M
Price / Earnings ratio: -1.2x
EPS (TTM): -$1.39
Volume: Loading
52-week high: $19.40
52-week low: $1.31

Source: third-party data provider, as of November 13, 2026

Compare with TENX

Technical indicators

RSI 14: 42.96
MACD 12/26/9: -0.09
EMA 9 of MACD: -0.12
MACD histogram: 0.03
SMA 50: $1.80; Price below SMA 50
EMA 50: $2.62; Price below EMA 50
SMA 200: $9.53; Price below SMA 200
EMA 200: $7.92; Price below EMA 200

Calculated by Gotrade from daily closing prices, as of November 11, 2026. Technical data, not a recommendation.

Analyst ratings

Analyst consensus: Hold

Based on 1 analyst rating

Strong Sell0

Sell0

Hold1

Buy0

Strong Buy0

Third-party analyst opinion, not a recommendation from Gotrade.

Financials

Performance

Revenue

Net income

Net margin %

2021

2022

2023

2024

2025

0000

Debt & Balance Sheet

Total assets

Total liabilities

2021

2022

2023

2024

2025

125M83M41M0

Revenue to Profit

2025

$0.0

Revenue

$0.0

Cost of revenue

$0.0

Gross profit

$0.0

Operating expenses

$-52.6M

Net income

Earnings

No data available

Source: third-party data provider

About Tenax Therapeutics, Inc. Common Stock

Tenax Therapeutics Inc is a phase three, development-stage pharmaceutical company focused on identifying and developing therapeutics that address cardiovascular and pulmonary diseases with high unmet medical need, with an initial therapeutic focus on pulmonary hypertension. Its drug development pipeline comprises: Levosimendan, a novel, first-in-class K-ATP activator and calcium sensitizer developed for intravenous use in hospitalized patients with acutely decompensated heart failure; and Imatinib, as a potential therapy for pulmonary arterial hypertension. The company is currently conducting clinical trials only for levosimendan as its prioritized product candidate to evaluate its potential to help patients with pulmonary hypertension.

SectorHealthcare

IndustryBiotechnology

Employees14

CEOMr. Christopher T. Giordano

IPO DateJan 2, 1997

HeadquartersChapel Hill, NC

Key Executives

Name	Title	Year Born
Mr. Christopher T. Giordano	CEO, President & Director	1975
Mr. Thomas R. Staab II, CPA	Chief Financial Officer	1968
Mr. Thomas A. McGauley	Principal Financial Officer & Principal Accounting Officer	1973
Dr. Stuart Rich M.D.	Chief Medical Officer & Director	1950
Mr. Doug Randall	Chief Business Officer	—
Dr. Douglas Hay Ph.D.	Executive Vice President of Regulatory Affairs	—
Mr. Timothy G. Healey M.B.A.	Chief Commercial Officer	1966
Dr. So-Young Kim M.D.	Executive Vice President of Clinical Development & Strategy	—

	Jan	Feb	Mar	Apr	May	Jun	Jul	Aug	Sep	Oct	Nov	Dec
2026			+5.4	-18.1	-7.1	+21.6	+3.1	-87.2	+5.0	-7.3	-6.1

Stocks in the same sector

Vertex Pharmaceuticals

ABEO

Abeona Therapeutics Inc.

FAQ

Buying Tenax Therapeutics, Inc. Common Stock (TENX) stock is now easy and instant through the Gotrade app.

Download the Gotrade app from the App Store or Google Play.
Create an account and verify your identity.
Make a deposit.
Search for the code "TENX", then tap "Trade".
Tap the "Buy" button.
Enter the amount you want to buy. You have two options:
1. Buy TENX by number of shares.
2. Buy fractional shares in dollars, starting from $1.
Swipe up to confirm your order, and you're done!

On Gotrade, you don't have to buy a full share. With fractional shares, you can start investing in Tenax Therapeutics, Inc. Common Stock from just $1. A small budget shouldn't stop you from building a US stock portfolio.

At the moment, Tenax Therapeutics, Inc. Common Stock (TENX) does not pay dividends because it focuses on reinvesting profits for company growth (a growth stock). However, you can still potentially earn profit from share price increases (capital gains). Track TENX's performance via the price chart in the Gotrade app.

Gotrade is the trading name of Gotrade Securities Inc., which is registered with and supervised by the Labuan Financial Services Authority (LFSA).

You can place an order any time. It goes through when the US market (NYSE/NASDAQ) opens: 9:30 AM to 4:00 PM New York time, Monday to Friday. Pre-market and after-hours trading are open too.

The market is closed on US public holidays. The Gotrade app shows whether the market is open.

There's no single perfect answer, but common approaches include:

Compare valuation (e.g., P/E, P/S) against historical averages or competitors.
Review revenue and earnings growth.
Check margins and cash flow.
Evaluate business outlook and the company's position within its industry.

You can combine fundamental analysis with an investing strategy that matches your risk profile. All of the information above can be viewed directly in the Gotrade app.

Trade Faster. Easier. Smarter.

#ReadyGoTrade

Welcome Reward up to $1,888

Create an account and trade US stocks on Gotrade

Download app

*Terms & conditions apply

Tenax Therapeutics, Inc. Common Stock (TENX) Stock

Key stats

Compare with TENX

Recent news

Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop

Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop

Technical indicators

Analyst ratings

Financials

Performance

Debt & Balance Sheet

Revenue to Profit

Earnings

Latest news

Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

Securities Fraud Class Action Filed Against Tenax Therapeutics, Inc.: Glancy Prongay Wolke & Rotter LLP Announces Lead Plaintiff Deadline

Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

Securities Fraud Class Action Lawsuit Pending Against Tenax Therapeutics, Inc.: The Law Offices of Howard G. Smith Highlights Lead Plaintiff Deadline

Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

Securities Fraud Lawsuit Filed Against Tenax Therapeutics, Inc.: The Law Offices of Frank R. Cruz Outlines Lead Plaintiff Deadline

Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop

Lost Money on Tenax Therapeutics, Inc. Stock? Glancy Prongay Wolke & Rotter LLP Investigates Possible Securities Fraud After 89.77% Share Price Drop

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G.

Did You Lose Money on Tenax Therapeutics, Inc. Stock? The Law Offices of Howard G.

TENX INVESTOR DEADLINE: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit

TENX INVESTOR DEADLINE: Tenax Therapeutics, Inc. Investors with Substantial Losses May Seek to Lead Class Action Lawsuit

Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R.

Lost Money on Tenax Therapeutics, Inc. Shares? The Law Offices of Frank R.

Rosen Law Firm Urges Tenax Therapeutics, Inc. (NASDAQ: TENX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Rosen Law Firm Urges Tenax Therapeutics, Inc. (NASDAQ: TENX) Stockholders with Large Losses to Contact the Firm for Information About Their Rights

Investor Alert: Robbins LLP Informs Investors of the Tenax Therapeutics, Inc. Class Action Lawsuit

Investor Alert: Robbins LLP Informs Investors of the Tenax Therapeutics, Inc. Class Action Lawsuit

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

TENX Investors Have Opportunity to Join Tenax Therapeutics, Inc. Fraud Investigation with SBS Law

About Tenax Therapeutics, Inc. Common Stock

Key Executives

Fundamentals

Valuation

Profitability

Trading

Technical indicators

Analyst views

Seasonality

Compare stocks

Market cap

Price / Earnings ratio

Price / Sales ratio

Dividend yield

Average volume

Earnings per share

Stocks in the same sector

FAQ

Trade Faster. Easier. Smarter.

#ReadyGoTrade